Alzheimer Disease — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Offer a cholinesterase inhibitor with monitoring of cognition, function, pulse, weight and adverse effects
The best answer is “Offer a cholinesterase inhibitor with monitoring of cognition, function, pulse, weight and adverse effects”. Donepezil, rivastigmine or galantamine can provide modest symptomatic benefit in mild-to-moderate Alzheimer disease. Review includes bradycardia, syncope, gastrointestinal effects, weight and whether function benefits. Care also requires advance planning, driving and medication-safety review, carer support and vascular-risk management; antipsychotics and sedatives can worsen harm.
Reference: Dementia Australia: Clinical resources for health professionals: https://www.dementia.org.au/professionals